The Malaysian Reserve

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to ...

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving ...